Regdanvimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A neutralizing, human immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration, regdanvimab specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - CTP 59 - CTP-59 - CTP59 - REGDANVIMAB